Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 22Recruiting 10Terminated 8Withdrawn 2Unknown 2Not yet recruiting 2Active not recruiting 2Available 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 112Gastrointestinal 36Thoracic 25Genitourinary 25Other hematologic neoplasm 22Lymphoid 19CNS 18Breast 16Gynecologic 15Sarcoma 10Plasma cell 10Head & Neck 9Dermatologic 8Classical hematology 7Other 5Myeloid 4Other solid neoplasm 2NET 2Endocrine 2Other neoplasm 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 5Pheochromocytoma 4Paraganglioma 3Gastro-enteropancreatic neuroendocrine tumor 3Vipoma 2Neoplasms 2Insulinoma 2Carcinoma, Merkel Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms, Cystic, Mucinous, and Serous 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Liver Neoplasms 1Hypoglycemia 1Glucagonoma 1Gastrinoma 1Diarrhea 1Carcinoma, Medullary 1Cachexia 1Adrenal Gland Neoplasms 1

Interventions

telotristat ethyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × NET × Clear all
NCT04034745 2020-12-30

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

Cedars-Sinai Medical Center

Withdrawn
EndocrineGastrointestinalNET

Cachexia, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

NCT02030184 2019-10-17

Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

University of Maryland, Baltimore

Phase 1/2 Withdrawn
EndocrineNETThoracic

Lung Neoplasms, Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡